Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | NCI-H1703 is a human lung squamous cell carcinoma cell line established in 1987 by A.F. Gazdar and J.D. Minna at the NCI–Navy Medical Oncology Branch, located at the National Naval Medical Center in Bethesda, Maryland. The cell line was derived from a 54-year-old Caucasian male patient with stage 1 lung cancer and a 50 pack-year smoking history. These cells grow as an adherent epithelial monolayer with a doubling time of approximately 48 hours. The genetic profile of NCI-H1703 includes a homozygous alteration at the splice donor site of TP53 (at the boundary of intron 8) and a homozygous CDKN2A p.Asp84Val mutation—a combination of mutations characteristic of lung squamous cell carcinoma. Furthermore, the cell line is microsatellite stable. It is widely used in research concerning the biology of lung squamous cell carcinoma, p53 mutations, proteomic and secretomic profiling, phosphotyrosine signaling pathways, as well as large-scale pharmacogenomic studies and CRISPR-based genetic dependency screens. |
| Tissue | Lung (primary tumor, in situ) |
| Disease | Lung Squamous Cell Carcinoma (Non-Small Cell Lung Carcinoma); stage 1 |
| Morphology | Epithelial |
| Gender | Male |
| Age | 54 years |
| Ethnicity | Caucasian |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Biology and translational research in pulmonary squamous cell carcinoma; 2. Analysis of TP53 mutations and the p53 pathway in non-small cell lung cancer; 3. Characterization via proteomics, secretomics, and reverse-phase protein arrays; 4. Profiling of phosphotyrosine and kinase signaling pathways; 5. Large-scale pharmacogenomics and CRISPR-based dependency screening; 6. Analysis of genomic alteration profiles and classification of lung cancer. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Doubling Time | Approximately 47.9 hours |
| Microsatellite Instability | Stable (MSS) |
| Genetic Profile | TP53 c.919+1G>T (IVS8+1G>T) splice donor mutation, homozygous; CDKN2A p.Asp84Val (c.251A>T), homozygous |
| Culture Conditions and Handling | |
| Subculturing | 1. Remove and discard the culture medium. 2. Briefly rinse the cell monolayer with PBS (Ca²⁺/Mg²⁺-free) to thoroughly remove residual serum. 3. Add 2.0 to 3.0 mL of 0.25% Trypsin–0.53 mM EDTA solution, and observe under an inverted microscope until the cell monolayer has dispersed (typically takes 2 to 5 minutes). 4. Add 6.0 to 8.0 mL of complete growth medium, and gently pipette to prepare a single-cell suspension. 5. Aliquot the cell suspension into new culture vessels. |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | A split ratio of 1:3 to 1:6 is recommended. |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Complete growth medium supplemented with 5% (v/v) DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR01222 | Luciferase Reporter Cell Line - NCI-H1703 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.